BRIEF

on Jaguar Health, Inc. (NASDAQ:JAGX)

Jaguar Health Launches Neonorm Dog for Digestive Support

Stock price chart of Jaguar Health, Inc. (EBR:JAGX) showing fluctuations.

Jaguar Health, Inc. has initiated the commercial launch of Neonorm Dog, expanding its Neonorm franchise beyond foals and calves to include canines. The plant-based product aims to support normal stool consistency and gastrointestinal fluid balance in dogs, offering a non-prescription option for pet owners.

Ian Wendt, Chief Business Officer at Jaguar, highlighted the company's dedication to providing a science-based solution for common digestive issues. The new product will soon be available on major platforms like Amazon and Chewy, making it easily accessible to consumers.

Neonorm Dog is derived from the Croton lechleri tree and provides a natural alternative to manage digestive episodes in dogs. Jaguar's CEO, Lisa Conte, emphasized the importance of having a reliable product at hand before symptoms arise. This launch is part of Jaguar's strategy to strengthen its presence in the companion animal market.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Jaguar Health, Inc. news